90050-52-5

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-N-methyl-5-nitrobenzamide is used as a precursor in the development of new drugs due to its unique structure and reactivity. Its potential biological activity makes it a valuable compound for exploring its therapeutic effects and applications in medicine.
Used in Research Applications:
In the field of research, 3-Bromo-N-methyl-5-nitrobenzamide serves as a research tool for studying various biochemical processes. Its distinct chemical properties allow scientists to investigate its interactions with biological systems and understand its role in different biological pathways.
Used in Organic Synthesis:
3-Bromo-N-methyl-5-nitrobenzamide is also utilized in the synthesis of other organic compounds. Its unique structure and reactivity make it a versatile building block for creating a variety of chemical entities, contributing to the advancement of organic chemistry and the development of novel compounds with potential applications in various industries.

InChI:InChI=1/C8H7BrN2O3/c1-10-8(12)5-2-6(9)4-7(3-5)11(13)14/h2-4H,1H3,(H,10,12)

Upstream product

• 74-89-5 methylamine 
• 51339-40-3 3-bromo-5-nitrobenzoyl chloride 
• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 121-92-6 3-nitrobenzoic acid 

Downstream Products

• 675122-46-0 5-(3-bromo-5-nitrophenyl)-1-methyl-1H-tetraazole 
• 675122-49-3 phenyl 3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenylcarbamate 
• 852660-89-0 N-{(1R,3R,4S)-4-{[[2,2-dimethyl-3-(4-fluorophenyl)propyl](methyl)amino]methyl}-3-[({[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]amino}carbonyl)amino]cyclohexyl}-N-methylacetamide 
• 852660-52-7 N-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-N'-((1R,2S)-2-{[((2RS)-6-fluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino]methyl}cyclohexyl)urea 
• 852660-57-2 N-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]-N'-((1R,2S)-2-{[((2RS)-6-fluoro-1,2,3,4-tetrahydronaphthalen-2-yl)(methyl)amino]methyl}cyclohexyl)urea 
• 852661-64-4 N-((1R,2S)-3-{cyclohexyl[3-(4-fluorophenyl)propyl]amino}-2-hydroxy-1-methylpropyl)-N'-[3-ethyl-5-(1-methyl-1H-tetrazol-5-yl)phenyl]urea 
• 675122-47-1 1-methyl-5-(3-nitro-5-vinylphenyl)-1H-tetraazole 
• 675122-48-2 3-Ethyl-5-(1-methyl-1H-tetrazole-5-yl)aniline 
• 1445790-17-9 3-(cyclopent-1-en-1-yl)-N-methyl-5-nitrobenzamide 

Relevant academic research and scientific papers

SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS

Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: The discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis

Conformational analysis of trans-1,2-disubstituted cyclohexane CCR3 antagonist 2 revealed that the cyclohexane linker could be replaced by an acyclic syn-α-methyl-β-hydroxypropyl linker. Synthesis and biological evaluation of mono- and disubstituted propyl linkers support this conformational correlation. It was also found that the α-methyl group to the urea lowered protein binding and that the β-hydroxyl group lowered affinity for CYP2D6. Ab initio calculations show that the α-methyl group governs the spatial orientation of three key functionalities within the molecule. α-Methyl-β-hydroxypropyl urea 31 with a chemotaxis IC50 = 38 pM for eosinophils was chosen to enter clinical development for the treatment of asthma.

ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.

N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of chemokine receptors of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

Substituted fused bicyclic amines as modulators of chemokine receptor activity

The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5′, R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

N-substituted heterocyclic amines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY.

The present application describes N-ureidoalkyl piperidines as modulators of chemokine receptors, or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.